Oncodesign, Covalab, CheMatech and ABX-CRO launch DRIVE™-MRT
A premium complete, integrated service offer for radiopharmaceuticals drug discovery and generation
Complementary expertise for successful progress at each stage of your development
After the discovery and proof-of-concept phases, the preclinical development of new therapeutic entities is a critical step for the regulatory approval of the first-in-man administration and the transition to the early phases of clinical trials.
D-VLOP, a network of expert partners all renowned and experienced in preclinical and clinical development, is the solution to successfully complete this phase.
Together with our partners Cynbiose, ERBC and PharmaLexwe bring you advice and support to define and implement your pre-clinical and clinical strategic program in line with your requirements and those of the regulatory authorities.
- Oncodesign: From target to the IND for new targeted and innovative therapies
- Cynbiose: Exploratory studies in pharmacology, safety and proof of concept using translational models in non-human primates
- ERBC: Regulatory preclinical safety and toxicity studies
- PharmaLex : Clinical development, pharmacovigilance and regulatory affairs
D-VLOP addresses all the needs of start-ups, small and medium biotechnology companies that need expertise in the preclinical and clinical phases of drug development, but also large pharmaceutical companies with specialized development needs.
The advantages of the D-VLOP offer
- The pharmaceutical culture, quality and expertise of experienced scientists and developers to successfully develop your new therapeutic entity.
- Cutting-edge and well established technological platforms meeting the needs and requirements of regulatory development.
- A holistic vision of the drug development process, knowledge of the state of the art and an understanding of the challenges of tomorrow.
- An ability to set up an appropriate steering and project support structure adapted to your needs.
